ALNY
Alnylam Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$43.81B
P/E Ratio
141.78
EPS
$2.33
Beta
0.38
52W High
$495.55
52W Low
$205.87
50-Day MA
$327.88
200-Day MA
$393.35
Dividend Yield
—
Profit Margin
8.45%
Forward P/E
36.10
PEG Ratio
0.64
About Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $3.71B |
| Gross Profit (TTM) | $3.03B |
| EBITDA | $557.24M |
| Operating Margin | 12.00% |
| Return on Equity | 73.30% |
| Return on Assets | 6.81% |
| Revenue/Share (TTM) | $28.35 |
| Book Value | $5.96 |
| Price-to-Book | 53.58 |
| Price-to-Sales (TTM) | 11.80 |
| EV/Revenue | 10.95 |
| EV/EBITDA | 64.39 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 84.90% |
| Shares Outstanding | $132.62M |
| Float | $132.08M |
| % Insiders | 0.47% |
| % Institutions | 101.74% |
Analyst Ratings
Consensus ($449.32 target)
6
Strong Buy15
Buy7
HoldData last updated: 4/7/2026